m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00462
 [1], [2], [3]
m6A modification CSF1 CSF1 METTL3 Methylation : m6A sites Indirect Enhancement RNA modification MIR149 MIR149 METTL1 Methylation : modification sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Macrophage colony-stimulating factor 1 (CSF1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> N7-methylguanosine (m7G)
Epigenetic Regulator Methyltransferase-like protein 1 (METTL1) WRITER View Details
Regulated Target MicroRNA 149 (MIR149) View Details
Crosstalk Relationship m7G  →  m6A Enhancement
Crosstalk Mechanism RNA modification indirectly impacts m6A modification through downstream signaling pathways
Crosstalk Summary METTL1 interacts with MicroRNA 149 (MIR149), increasing it's m7G level and promoting its physical interaction with Macrophage colony-stimulating factor 1 (CSF1), which was regulated by METTL3-mediated m6A modification.
In-vitro Model
 TOV-112D Ovarian endometrioid adenocarcinoma Homo sapiens CVCL_3612
SW480 Colon adenocarcinoma Homo sapiens CVCL_0546
SW620 Colon adenocarcinoma Homo sapiens CVCL_0547
HCT 116 Colon carcinoma Homo sapiens CVCL_0291
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Macrophage colony-stimulating factor 1 (CSF1) 4 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name RG7155 Phase 2 [4]
MOA Antagonist
External Link
TTD: D06NQH
 Compound Name Emactuzumab Phase 1 [5]
MOA Antagonist
External Link
TTD: D00MJI
 Compound Name PLX73086 Phase 1 [4]
MOA Antagonist
External Link
TTD: D0PL8D
 Compound Name MSC110 Phase 1 [6]
Synonyms
Lacnotuzumab
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D18QIB
References
Ref 1 METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP. Cell Biol Int. 2020 Dec;44(12):2524-2531. doi: 10.1002/cbin.11459. Epub 2020 Sep 11.
Ref 2 Overexpressed methyltransferase-like 1 (METTL1) increased chemosensitivity of colon cancer cells to cisplatin by regulating miR-149-3p/S100A4/p53 axis. Aging (Albany NY). 2019 Dec 20;11(24):12328-12344. doi: 10.18632/aging.102575. Epub 2019 Dec 20.
Ref 3 miR-149 Suppresses Breast Cancer Metastasis by Blocking Paracrine Interactions with Macrophages. Cancer Res. 2020 Mar 15;80(6):1330-1341. doi: 10.1158/0008-5472.CAN-19-1934. Epub 2020 Jan 7.
Ref 4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 6 Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019 Jun;369(3):428-442.